You are here

Home » Home » Research

PeaPure Palmitoylethanolamide Abstracts

PeaPure Palmitoylethanolamide Abstracts

Palmitoylethanolamide Medical and Scientific Articles

palmitoylethanolamide, endocannabinoid , CB 2, GPR55 & GPR119 agonist

  1. The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? (abst – 1999) 
  2. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells (full – 2001)
  3. Administration of Endocannabinoids Prevents a Referred Hyperalgesia Associated With Inflammation of the Urinary Bladder (full – 2001)
  4. Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. (abst – 2001)
  5. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat (full – 2002)
  6. Endocannabinoids and related fatty acid derivatives in pain modulation. (abst – 2002)
  7. The search for the palmitoylethanolamide receptor. (abst – 2005)
  8. Finding of endocannabinoids in human eye tissues: implications for glaucoma. (abst – 2005)
  9. Selective antiepileptic effects of N-palmitoylethanolamide, a putative endocannabinoid. (abst – 2005)
  10. Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. (abst – 2006)
  11. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. (full – 2008)
  12. Endocannabinoids and nutrition. (full – 2008)
  13. ‘Entourage’ effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. (full – 2008)
  14. Adjuvant treatment of atopic eczema: assessment of an emollient containing Npalmitoylethanolamine (ATOPA study). (abst – 2008)
  15. Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. (abst – 2008)
  16. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. (full – 2009)
  17. Receptors for acylethanolamides-GPR55 and GPR119. (full – 2009)
  18. Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain (full – 2009)
  19. Anti-inflammatory effect of palmitoylethanolamide on human adipocytes. (abst – 2009)
  20. Plasma endocannabinoid levels in multiple sclerosis. (abst – 2009)
  21. N-acylethanolamines, anandamide and food intake. (abst – 2009)
  22. Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. (full – 2010)
  23. Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls (full – 2010)
  24. Endocannabinoids and Human Sperm Cells (link to PDF – 2010)
  25. Protective role of palmitoylethanolamide in contact allergic dermatitis. (abst – 2010)
  26. Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. (abst – 2010)
  27. Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. (abst – 2010)
  28. Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. (abst – 2010)
  29. Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations. (abst – 2010)
  30. Protective role of palmitoylethanolamide in contact allergic dermatitis. (abst – 2010)
  31. Misdiag nosed chronic pelvic pain: pudendal neuralgia responding to a novel use of palmitoylethanolamide. (abst – 2010) 
  32. Chocolate: The Good, the Bad and the Angry (news – 2010)
  33. Increasing Antiproliferative Properties of Endocannabinoids in N1E-115 Neuroblastoma Cells through Inhibition of Their Metabolism. (full – 2011)
  34. Administration of URB597, oleoylethanolamide or palmitoylethanolamide increases waking and dopamine in rats. (full – 2011)
  35. Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats (full – 2011)
  36. Ocular Hypotensive Effect of Oral Palmitoyl-ethanolamide: A Clinical Trial (full – 2011)
  37. Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice (full – 2011)
  38. Palmitoylethanolamide counteracts reactive astrogliosis induced by beta-amyloid peptide. (abst – 2011)
  39. Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. (abst – 2011)
  40. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. (abst – 2011)
  41. Anandamide and its congeners inhibit human plasma butyrylcholinesterase. Possible new roles for these endocannabinoids? (abst – 2011)
  42. Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. (abst – 2011)
  43. Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α.(full – 2012)
  44. The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action (full – 2012)
  45. The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation (full – 2012)
  46. Endocannabinoids measurement in human saliva as potential biomarker of obesity. (full – 2012)
  47. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series (full – 2012)
  48. Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α (full – 2012)
  49. The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action (full – 2012)
  50. Effects of Palmitoylethanolamide on Aqueous Humor Outflow. (abst – 2012)
  51. The interaction between intrathecal administration of low doses of palmitoylethanolamide and AM251 in formalin-induced pain related expression in rats. (abst – 2012) 
  52. Medial prefrontal cortex endocannabinoid system modulates baroreflex activity through CB1 receptors (abst – 2012)
  53. Effects of palmitoylethanolamide on intestinal injury and inflammation caused by ischemia-reperfusion in mice (abst – 2012)
  54. Review article: Mast cell–glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide (abst – 2012)
  55. Inhibition Of Fatty Acid Amide Hydrolase Produces Anti-Tussive Effects In Guinea-Pigs: Evidence For Elevated Fatty Acid Amides Acting Via Cannabinoid Receptors On Airway Sensory Nerves (abst – 2012)
  56. THE CO-EXPRESSION OF THE ENDOCANNABINOID SYSTEM AND THE RANK/RANKL SIGNALLING PATHWAY IN HUMAN BONE AND OSTEOCLAST CULTURE (abst – 2012)
  57. The Novel Reversible Fatty Acid Amide Hydrolase Inhibitor ST4070 Increases Endocannabinoid Brain Levels and Counteracts Neuropathic Pain in Different Animal Models (abst – 2012)
  58. Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans: a pilot study. (abst – 2012)
  59. Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. (abst – 2012)
  60. Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor. (abst – 2012)
  61. Serum Metabolic Profiling Study of Hepatocellular Carcinoma Infected with Hepatitis B or Hepatitis C Virus by Using Liquid Chromatography-Mass Spectrometry. (abst – 2012)
  62. Optimized synthesis and characterization of N-acylethanolamines and Oacylethanolamines, important family of lipid-signalling molecules. (abst – 2012)
  63. Temporal changes in N-acylethanolamine content and metabolism throughout the periadolescent period (abst – 2012)
  64. Acute Stress Increases Circulating Anandamide and Other N-Acylethanolamines in Healthy Humans (abst – 2012)
  65. Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. (abst – 2012)
  66. Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-α, PPAR-
Subscribe to FitEyes.com RSS Feed